Vertex Pharmaceuticals Statistics
Vertex Pharmaceuticals (VX1) Stock Statistics & Valuation Metrics
Total Valuation
Vertex Pharmaceuticals has a market cap or net worth of EUR 123.89B. The enterprise value is EUR 133.59B.
- Market Cap
- EUR 123.89B
- Enterprise Value
- EUR 133.59B
Share Statistics
Vertex Pharmaceuticals has 253,537,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 253,537,670
- Owned by Insiders
- 0.20%
- Owned by Institutions
- 94.30%
Financial Efficiency
Vertex Pharmaceuticals’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 18.54%.
- Return on Equity (ROE)
- 0.21
- Return on Assets (ROA)
- 0.15
- Return on Invested Capital (ROIC)
- 18.54%
- Return on Capital Employed (ROCE)
- 0.22
- Revenue Per Employee
- 1.89M
- Profits Per Employee
- 617.69K
- Employee Count
- 6,400
- Asset Turnover
- 0.47
- Inventory Turnover
- 1.07
Valuation Ratios
The current PE Ratio of Vertex Pharmaceuticals is 34.39. Vertex Pharmaceuticals’s PEG ratio is 3.71.
- PE Ratio
- 34.39
- PS Ratio
- 10.51
- PB Ratio
- 6.53
- Price to FCF
- 42.64
- Price to Operating Cash Flow
- 36.96
- PEG Ratio
- 3.71
Income Statement
In the last 12 months, Vertex Pharmaceuticals had revenue of 12.07B and earned 3.95B in profits. Earnings per share was 15.46.
- Revenue
- 12.07B
- Gross Profit
- 10.27B
- Operating Income
- 4.76B
- Pretax Income
- 4.64B
- Net Income
- 3.95B
- EBITDA
- 4.87B
- Earnings Per Share (EPS)
- 15.46
Cash Flow
In the last 12 months, operating cash flow was 3.69B and capital expenditures -492.30M, giving a free cash flow of 3.20B billion.
- Operating Cash Flow
- 3.69B
- Free Cash Flow
- 3.20B
- Free Cash Flow per Share
- 12.63
Dividends & Yields
Vertex Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.35%
- Earnings Yield
- 2.91%
Stock Price Statistics
- Beta
- 0.30
- 52-Week Price Change
- 28.84%
- 50-Day Moving Average
- 462.58
- 200-Day Moving Average
- 420.19
- Relative Strength Index (RSI)
- 56.27
- Average Volume (3m)
- 43
Important Dates
Vertex Pharmaceuticals upcoming earnings date is Feb 09, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 02, 2026
- Next Earnings Date
- Feb 09, 2027
- Ex-Dividend Date
- ―
Financial Position
Vertex Pharmaceuticals as a current ratio of 2.90, with Debt / Equity ratio of 10.88%
- Current Ratio
- 2.90
- Quick Ratio
- 2.46
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.63
- Interest Coverage Ratio
- 357.95
Taxes
In the past 12 months, Vertex Pharmaceuticals has paid 690.00M in taxes.
- Income Tax
- 690.00M
- Effective Tax Rate
- 0.15
Enterprise Valuation
Vertex Pharmaceuticals EV to EBITDA ratio is 27.79, with an EV/FCF ratio of 43.11.
- EV to Sales
- 10.63
- EV to EBITDA
- 27.79
- EV to Free Cash Flow
- 43.11
- EV to Operating Cash Flow
- 37.37
Balance Sheet
Vertex Pharmaceuticals has EUR 6.30B in cash and marketable securities with EUR 6.48B in debt, giving a net cash position of -EUR 175.10M billion.
- Cash & Marketable Securities
- EUR 6.30B
- Total Debt
- EUR 6.48B
- Net Cash
- -EUR 175.10M
- Net Cash Per Share
- -EUR 0.69
- Tangible Book Value Per Share
- EUR 39.31
Margins
Gross margin is 85.57%, with operating margin of 33.87%, and net profit margin of 30.61%.
- Gross Margin
- 85.57%
- Operating Margin
- 33.87%
- Pretax Margin
- 36.64%
- Net Profit Margin
- 30.61%
- EBITDA Margin
- 38.24%
- EBIT Margin
- 36.95%
Analyst Forecast
The average price target for Vertex Pharmaceuticals is EUR 552.92, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 552.92
- Price Target Upside
- 13.49% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 22
- Revenue Growth Forecast
- 5.62%
- EPS Growth Forecast
- 4.50%
Scores
- Smart Score
- 8
- AI Score
- ―

